The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|June 2, 2004
- Pharmaceutical Technology-06-02-2004
- Volume 28
- Issue 6
Microbial Testing in Support of Aseptic Processing
Author(s)Anthony M. Cundell
The role of microbial testing to ensure the sterility of aseptically filled sterile products is explained, from the product development phase to in-process monitoring to finished product testing.
Advertisement
Articles in this issue
over 22 years ago
June 2004over 22 years ago
Uniformity of Bioprocessing Equipment Manufacturingover 22 years ago
Research Tips To Find Packaging Facts Fastover 22 years ago
New Technologies Optimize Biotech Process Efficiencyover 22 years ago
Will CROs Take On the Risks of Strategic Outsourcing?over 22 years ago
Battles Escalate Over Prescription Drug Importsover 22 years ago
USP's Semi-Hemiquinquennial Meetingover 22 years ago
In the Spotlight - June 2004Advertisement
Related to this article
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
AI Formulation: Regulators Want Data
5